CME Snack

Addressing Racial Disparities in Patients with Schizophrenia: Making the Commitment to Do Better

Launch Date
08/31/2021
Credit Amount
0.00 Expired
Credit Expires
08/31/2022

Faculty

Rakesh Jain, MD, MPH
(he/him/his)
Clinical Professor, Department of Psychiatry
Texas Tech Health Sciences Center School of Medicine – Permian Basin
Midland, TX
Rakesh Jain, MD, MPH

Rakesh Jain, MD, MPH, is a Clinical Professor in the department of Psychiatry at the Texas Tech Health Sciences Center School of Medicine – Permian Basin in Midland, Texas and in private practice in Austin, Texas. Dr. Jain attended medical school at the University of Calcutta in India. He received his Master of Public Health (MPH) degree from the University of Texas School of Public Health in Houston, where he was awarded a National Institute/Center for Disease Control Competitive Traineeship. His research thesis focused on the impact of substance abuse.

Dr. Jain completed his residency in psychiatry at the Department of Psychiatry and Behavioral Sciences at the University of Texas Medical School at Houston. He then completed a postdoctoral fellowship in research psychiatry at the University of Texas Mental Sciences Institute in Houston. He was awarded the National Research Service Award in support of his postdoctoral fellowship.

Dr. Jain has been involved in over 100 research projects studying the effects of medications on short-term and long-term treatment of depression, anxiety, pain/mood overlap disorders, ADHD, and psychosis in adult and child/adolescent populations. He has presented at the World Psychiatric Congress held in Prague, and at Depression and Pain Forum meetings internationally. He is the author of 55 articles published in various journals and magazines, such as the Journal of Psychiatric Research and  Journal of Clinical Psychiatry, among others, and has presented over 25 original research posters at meetings such as the American Psychological Association (APA), the American College of Neuropsychopharmacology (ACNP), the American Academy of Child and Adolescent Psychiatry (AACAP), the U.S. Psychiatric Congress, and more. He has co-authored six books that range from patient education to cutting-edge neurobiologic findings in psychiatry and mental health. He serves on several advisory boards focusing on drug development and disease state education. He was also recently the Chair of the U.S. Psychiatric Congress, and for several years, has served as a member of the Steering Committee for U.S. Psychiatric Annual Congress. He is a recipient of the Public Citizen of the Year award from the National Association of Social Workers, Gulf Coast Chapter, in recognition of his community and peer education, and championing of mental health issues.

Oladunni Oluwoye, PhD, CHES
Assistant Professor, Elson S. Floyd College of Medicine, Washington State University
Co-Director, Washington State Center of Excellence in Early Psychosis, Spokane, WA
Oladunni Oluwoye, PhD, CHES

Dr. Oladunni Oluwoye is an Assistant Professor in the Elson S. Floyd College of Medicine at Washington State University and the Co-Director of Washington State Center of Excellence in Early Psychosis. She serves as one of the lead evaluators for New Journeys, a network comprised of 11 coordinated specialty care programs in Washington State. Overall, her research is focused on improving pathways to care for the Black/African American community and family engagement in coordinated specialty care, reducing racial and ethnic inequities in mental health service utilization, and improving services for individuals with co-occurring substance use disorders and serious mental illness.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credits

Statement of Need

Schizophrenia is a persistent, debilitating disease that depletes individuals and their families of their general well-being, as well as psychosocial and cognitive functioning. Compounding its impact, racial disparities exist in the diagnosis and management of schizophrenia, resulting in racially and ethnically diverse individuals being less likely to have access to mental health services, seek out services, or receive needed care. Racially and ethnically diverse populations, however, are more likely to receive poor quality of care and end services prematurely.

Guided by the perspectives of racially and ethnically diverse individuals living with schizophrenia, the final installment in this CME Outfitters Snack series will provide clinicians with tools and strategies to address racial disparities in the diagnosis and management of schizophrenia, including strategies for improving cultural sensitivity, establishing trust, and engaging patients in shared decision-making.

Learning Objectives

At the end of this CME/CE activity, participants should be able to implement strategies to address racial disparities in the diagnosis and management of schizophrenia by removing implicit bias, establishing trust, providing education, and engaging in shared decision-making.

Financial Support

Supported by an educational grant from Alkermes

Target Audience

Psychiatrists, psychiatric residents, psychiatric nurses, primary care physicians, PAs, nurse practitioners, and pharmacists.

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians (ACCME) 0.75

CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CME Outfitters, LLC, designates this enduring activity for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 0.75

This activity is designated for 0.75 contact hour. Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)™ from Jointly Accredited Organizations. Nurse practitioners can also apply for credit through their state boards.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit ™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit ™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Note for California Nurses

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Pharmacists/Pharmacy Tech (ACPE) 0.75

This application-based activity is approved for 0.75 contact hour (0.075 CEUs) of continuing pharmacy credit.
Activity UAN: JA0007185-0000-21-023-H01-P

PAs (AAPA) 0.75

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 0.75

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.

Dr. Jain reports that he receives research support from Allergan; Lilly; Lundbeck; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Shire Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc. He is on the advisory board for Alkermes; Janssen Pharmaceuticals, Inc.; Lilly; Lundbeck; Merck & Co., Inc.; Neos Therapeutics, Inc.; Neurocrine Biosciences, Inc.; Otsuka America Pharmaceutical, Inc.; Pamlab; Pfizer Inc.; Shire Pharmaceuticals; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for Acadia; Alfasigma USA, Inc.; Allergan; Eisai; Evidera; Impel; Janssen Pharmaceuticals, Inc.; Lilly; Lundbeck; Merck & Co., Inc.; Neos Therapeutics, Inc.; Neurocrine Biosciences, Inc.; Osmotica; Otsuka America Pharmaceutical, Inc.; Pamlab; Pfizer Inc.; Shire Pharmaceuticals; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He is on the speakers board for Ironshore Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Lilly; Lundbeck; Merck & Co., Inc.; Neos Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Pamlab; Pfizer Inc.; Shire Pharmaceuticals; Sunovion Pharmaceuticals Inc.; Takeda; Takeda Pharmaceuticals U.S.A., Inc.; and Tris Pharmaceuticals.

Dr. Oluwoye has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

  • Jeffrey Helfand, DO (peer reviewer)
  • Mae Ochoa, RPh (peer reviewer)
  • Kashemi D. Rorie, PhD (planning committee)
  • Evan Luberger (planning committee)
  • Jan Perez (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credits

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Questions about this activity?

Call us at (877) CME-PROS or (877) 263-7767.

SN-142-083121-84

 

Addressing Racial Disparities in Patients with Schizophrenia: Making the Commitment to Do Better
Event Date: 08/31/2021